Skip to main content
SpringerLink
Log in

Interethnic Differences in Drug Disposition and Response: Relevance for Drug Development, Licensing, and Registration

  • Chapter
Pharmacokinetics of Drugs

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 110))

Abstract

In 1982, Kalow introduced his review on “Ethnic differences in drug metabolism” by stating that: “the literature contains a number of examples of differences between populations in drug metabolizing capacity. Although this topic has been discussed previously as part of pharmacogenetics review, it deserves a new effort with different emphasis on a recently expanded data base. The topic should help improve understanding of human biology, and is of practical significance in pharmacology and toxicology.” Ten years later the same statement is still true and considerable knowledge has been acquired at the molecular biology level. As a matter of fact, a recently published book on pharmacogenetics (Kalow 1992) contains important and extensive information on interethnic differences in drug metabolism. Accordingly, the authors of the present review decided to concentrate their presentation on aspects related essentially to drug development, licensing, and registration in the context of the new “4 W” environment (i.e., What and Why to present for World Wide drug registration). In this framework, pharmacokinetic/ pharmacodynamic (PK/PD) relationships are also becoming of importance, as exemplified by a recent conference (PECK et al. 1992), and the authors felt that their presentation should deal also with some aspects of interethnic differences in drug tolerance and response. However, the wide-ranging subject of interethnic differences in drug response and tolerance will not be discussed in detail in the present review and interested readers are referred to treatises of internal medicine such as the Harrison’s (Braunwald et al. 1988). Nevertheless, PK/PD relationships will serve as a reference framework for this chapter on interethnic differences in drug metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allaz AF, Dayer P, Fabre J, Rudhardt M, Balant L (1979) Pharmacocinétique d’une nouvelle céphalosporin, la céfopérazone. Schweiz Med Wochenschr 109: 1999–2005

    PubMed  CAS  Google Scholar 

  • Alván G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533–537

    PubMed  Google Scholar 

  • Balant LP, Gorgia A, Tschopp JM, Revillard C, Fabre J (1976) Pharmacocinétique de deux médicaments bêta-bloquants: détection d’une anomalie pharmacogénétique? Schweiz Med Wochenschr 106: 1403–1407

    PubMed  CAS  Google Scholar 

  • Balant LP, Gundert-Remy U, Boobis AR, von Bahr C (1989) Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur J Clin Pharmacol 36: 551–554

    PubMed  CAS  Google Scholar 

  • Balant LP, Roseboom H, Gundert-Remy U (1990) Pharmacokinetic criteria for drug research and development. Adv Drug Res 19: 1–139

    CAS  Google Scholar 

  • Bertilsson L (1990) Interethnic differences in drug oxidation polymorphism. In: Alvan G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Pithan K (eds) European consensus conference on pharmacogenetics. Commission of the European Communities, Luxembourg, pp 171–178 (Coordinated action COST B1 )

    Google Scholar 

  • Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to Smephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 45: 348–355

    PubMed  CAS  Google Scholar 

  • Braunwald E et al. (eds) (1988) Harrison’s principles of internal medicine, 11th edn. McGraw-Hill, New York

    Google Scholar 

  • Darmansjah I, Muchtar A (1992) Dose-response variation among different populations. Clin Pharmacol Ther 52: 449–452

    PubMed  CAS  Google Scholar 

  • Dayer P, Balant LP, Courvoisier F, Küpfer A, Kubli A, Gorgia A, Fabre J (1982) The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 7: 73–77

    PubMed  CAS  Google Scholar 

  • Dayer P, Balant LP, Kiipfer, A, Courvoisier F, Fabre J (1983) Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol 24: 797–799

    PubMed  CAS  Google Scholar 

  • Dayer P, Balant LP, Küpfer A, Striberni R, Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol 28: 317–320

    PubMed  CAS  Google Scholar 

  • Ebelin ME, Steimer JL, Laplanche R, Niederberger W (1992) An evaluation of population pharmacokinetics during drug development: experiences with graphical exploratory analysis for isradipine and tropisetron. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation: the population approach. Commission of the European Communities, Luxembourg, pp 131–141 (Coordinated action COST B1 )

    Google Scholar 

  • Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective Noxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187

    PubMed  CAS  Google Scholar 

  • Evans DAP (1992) N-acetyltransferase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 95–178

    Google Scholar 

  • Ghoneim MM, Korttila K, Chiang CK, Jacobs L, Schoenwald RD, Mewaldt SP, Kabaya KO (1981) Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 29: 749–756

    PubMed  CAS  Google Scholar 

  • Gundert-Remy U (1992) Population approach in pharmacokinetic and pharmacodynamics—views within regulatory agencies: Europe. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation: the population approach. Commission of the European Communities, Luxembourg, pp 153–156 (Coordinated action COST B1 )

    Google Scholar 

  • Hermansson J, von Bahr C (1982) Determination of (R)- and (S)-alprenolol and (R)- and (S)-metoprolol diastereoisomeric derivatives in human plasma by reversedphase liquid chromatography. J Chromatogr 227: 113–127

    PubMed  CAS  Google Scholar 

  • Holford NHG (1992) Parametric models for the time course of drug action: the population approach. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation: the population approach. Commission of the European Communities, Luxembourg, pp 193–206 (Coordinated action COST B1 )

    Google Scholar 

  • Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, Lia CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46: 198–207

    PubMed  CAS  Google Scholar 

  • Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ (1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 23: 482–485

    PubMed  CAS  Google Scholar 

  • Joubert PH, Brandt HD (1990) Apparent racial difference in response to angiotensin I infusion. Eur J Clin Pharmacol 39: 183–185

    PubMed  CAS  Google Scholar 

  • Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7: 373–400

    PubMed  CAS  Google Scholar 

  • Kalow W (1984) Pharmacoanthropology: outline, problems, and the nature of case histories. Fed Proc 43: 2314–2318

    PubMed  CAS  Google Scholar 

  • Kalow W (1992) Pharmacoanthropology and the genetics of drug metabolism. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 865–877

    Google Scholar 

  • Katz MM, Katz MM, Kato M, Yamamoto J et al. (1979) Transcultural psychopharmacology in depression: East and West. Psychopharmacol Bull 15: 24–31

    Google Scholar 

  • Kubli A, Balant LP, Dayer P, Balant-Gorgia A, Fabre J (1982) Influence du polymorphisme génétique de l’oxydation sur les études de biodisponibilité: a propos du bufuralol. J Pharmacol Clin 1: 301–315

    CAS  Google Scholar 

  • Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ (1987) Differences in diazepam pharmacokinetics in Chinese and white Caucasians—relation to body lipid stores. Eur J Clin Pharmacol 32: 211–215

    PubMed  CAS  Google Scholar 

  • Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759

    PubMed  Google Scholar 

  • Lennard MS (1992) The polymorphic oxidation of beta-adrenoceptor antagonists. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 701–720

    Google Scholar 

  • Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LW, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolisers. Clin Pharmacol Ther 34: 732–737

    PubMed  CAS  Google Scholar 

  • Lou YC, Ying L, Bertilsson L, Sjoqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2: 852–853

    PubMed  CAS  Google Scholar 

  • Mahgoub A, Idle JR, Dring LG, Lancester R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586

    PubMed  CAS  Google Scholar 

  • Mendoza R, Smith MW, Poland RE, Lin KM, Strickland TL (1991) Ethnic psychopharmacology: the Hispanic and native American perspective. Psychopharmacol Bull 27: 449–461

    PubMed  CAS  Google Scholar 

  • Meyer UA, Zanger UM, Grant D, Blum M (1990) Genetic polymorphisms of drug metabolism. Adv Drug Res 19: 197–241

    CAS  Google Scholar 

  • Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408

    PubMed  CAS  Google Scholar 

  • Peck CC (1992) Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation: the population approach. Commission of the European Communities, Luxembourg, pp 157–168 (Coordinated action COST B1 )

    Google Scholar 

  • Peck CC, Barr WH, Benet LZ, et al. (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 51: 465–473

    PubMed  CAS  Google Scholar 

  • Sheiner LB (1992) Population approach in drug development: rationale and basic concepts. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation: the population approach. Commission of the European Communities, Luxembourg, pp 13–27 (Coordinated action COST B1 )

    Google Scholar 

  • Strickland TL, Ranganath V, Lin KM, Poland RE, Mendoza R, Smith MW (1991) Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacol Bull 27: 441–448

    PubMed  CAS  Google Scholar 

  • Vozeh S (1992) Applications of population approach to clinical pharmacokinetics and validation of results. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation: the population approach. Commission of the European Communities, Luxembourg, pp 107–120 (Coordinated action COST B1 )

    Google Scholar 

  • Yue QY, Bertilsson L, Dahl-Puustinen ML, Sawe J, Sjoqvist F, Johansson I, Ingelman-Sundberg M (1989) Dissociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 2: 870

    PubMed  CAS  Google Scholar 

  • Zhou HH, Wood AJJ (1990) Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)—and (+)-propranolol. Clin Pharmacol Ther 47: 719–723

    PubMed  CAS  Google Scholar 

I. Phenotypes of N-acetylation

  • Afonia AO, Arharwarien ED, Okotore RO, Femi-Pearse D (1979) Isoniazid acetylator phenotypes of Nigerians. Nigerian Med J 9: 86–88

    Google Scholar 

  • Airaksinen E, Mattila MJ, Olilla O (1969) Inactivation of isoniazid and sulphadimidine in Mongoloid subjects. Ann Med Exp Biol Fenn 47: 303–307

    PubMed  CAS  Google Scholar 

  • Armstrong AR, Peart HE (1960) A comparison between the behaviour of Eskimos and non-Eskimos to the administration of isoniazid. Am Rev Respir Dis 81: 588–594

    PubMed  CAS  Google Scholar 

  • Bouayad Z, Chevalier B, Maurin R, Bartal M (1982) Phénotype d’acétylation de l’isoniazide au Maroc. Etude preliminaire sur 100 cas. Rev Maroc Med Sante 4: 13–18

    Google Scholar 

  • Bozkurt A, Basci NE, Tuncer M, Kayaalp SO (1990) N-acetylation phenotyping with sulphadimidine in a Turkish population. Eur J Clin Pharmacol 38: 53–56

    PubMed  CAS  Google Scholar 

  • Bressolette L, Berthou F, Riche C, Mottier D, Floch HH (1990) Polymorphisme genetique d’acetylation et d’hydroxylation dans la population bretonne. Thérapie 45: 99–103

    Google Scholar 

  • Desai M, Jariwala G, Khokhani B, Desai NK, Sheth UK (1973) Isoniazid inactivation in Indian children. Indian Pediatr 10: 373–376

    PubMed  CAS  Google Scholar 

  • Eidus L, Hodgkin MM, Schaeffer O, Jessamine AG (1974) Distribution of isoniazid inactivators determined in Eskimos and Canadian college students by a urine test. Rev Can Biol 33: 117–123

    PubMed  CAS  Google Scholar 

  • Eidus L, Glatthaar E, Hodgkin MM, Nel EE, Kleeberg HH (1979) Comparison of isoniazid phenotyping of black and white patients with emphasis on South African blacks. Int J Clin Pharmac Biopharm 17: 311–316

    CAS  Google Scholar 

  • El-Yazigi A, Chaleby K, Martin CR (1989) Acetylator phenotypes of Saudi Arabians by a simplified caffeine metabolite test. J Clin Pharmacol 29: 246–250

    PubMed  CAS  Google Scholar 

  • Evans DAP, Paterson S, Francisco P, Alvarez G (1985) The acetylator phenotype of Saudi Arabian diabetics. J Med Genet 22: 479–483

    PubMed  CAS  Google Scholar 

  • Evans DAP, Wicks J, Higgins J, Assisto M (1991) The acetylator phenotypes of Saudi Arabians with coronary arterial atheroma. J Med Genet 28: 192–193

    PubMed  CAS  Google Scholar 

  • Eze LC (1987) High incidence of the slow nitrazepam acetylator phenotype in a Nigerian population. Biochem Genet 25: 225–229

    PubMed  CAS  Google Scholar 

  • Eze LC, Obidoa O (1978) The acetylation of sulphamethazine in a Nigerian population. Biochem Genet 16: 1073–1077

    PubMed  CAS  Google Scholar 

  • Fawcett IW, Gammon PT (1975) Determination of the acetylator phenotype in a Northern Nigerian population. Tubercle 56: 119–201

    Google Scholar 

  • Goedde HW, Benkmann HG, Agarwal DP, Kroeger A (1977a) Genetic studies in Ecuador; acetylator phenotypes, red cell enzyme and serum protein polymorphisms of Shuara indians. Am J Phys Anthropol 47: 419–425

    PubMed  CAS  Google Scholar 

  • Goedde HW, Flatz G, Rahimi AG, Kaifie S, Benkmann HG, Kreise G, Delbriick H (1977b) The acetylator polymorphism in four populations of Afghanistan. Hum Hered 27: 383–388

    PubMed  CAS  Google Scholar 

  • Gupta RC, Nair CR, Jindal SK, Malik SK (1984) Incidence of isoniazid acetylation phenotypes in North Indians. Int Clin Pharmacol Ther Toxicol 22: 259–264

    CAS  Google Scholar 

  • Gurumurthy P, Krisnamurthy MS, Nazareth O, Parthasarathy R, Raghupati Sarma G, Somasundaram PR, Tripathy SP, Ellard GA (1984) Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 129: 58–61

    PubMed  CAS  Google Scholar 

  • Hayward GA (1975) Human acetylation polymorphism in Polynesians. Proc Univ Otago Med Sch 53: 67–68

    Google Scholar 

  • Hilderbrand M, Seifert W (1989) Determination of acetylator phenotype in Caucasians with caffeine. Eur J Clin Pharmacol 37: 525–526

    Google Scholar 

  • Homeida M, Abboud OI, Dawi O, Rahama AM, Awad EH, Ahmed OM (1986) The acetylator phenotype of Sudanese subjects. Arab J Med 5: 30–31

    Google Scholar 

  • Horai Y, Ishizaki T (1988) N-acetylation polymorphism of dapsone in a Japanese population. Br J Clin Pharmacol 25: 487–494

    PubMed  CAS  Google Scholar 

  • Horai Y, Ishizaki T, Sasaki T, Koya G, Matsuyama K, Iguelin S (1982) Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic lupus erythematosus and control subjects. Br J Clin Pharmacol 13: 361–374

    PubMed  CAS  Google Scholar 

  • Horai Y, Zhou HH, Zhang LM, Ishizaki T (1988) Acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol 25: 81–87

    PubMed  CAS  Google Scholar 

  • Horai Y, Fujita K, Ishizaki T (1989) Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 37: 581–587

    PubMed  CAS  Google Scholar 

  • Inaba T, Arias TD (1987) On phenotyping with isoniazid. The use of urinary acetylation/ratios and the uniqueness of antimodes found in two Amerindian populations. Clin Pharmacol Ther 42: 493–497

    PubMed  CAS  Google Scholar 

  • Irshaid YM, Al-Halidi HF, Abuirjeie MA, Rawasheh NM (1991) N-acetylation phenotyping using dapsone in a Jordanian population. Br J Clin Pharmacol 32: 1039–1057

    Google Scholar 

  • Irshaid YM, Al-Hadidi HF, Abuirjeie MA, Latif A, Sartawi O, Rawashed NM (1992) Acelylator phenotype of Jordanian diabetics. Eur J Clin Pharmacol 43: 621–623

    PubMed  CAS  Google Scholar 

  • Islam SI (1982) Polymorphic acetylation of sulphamethyzine in rural Bedouin and urban-dwellers in Saudi Arabia. Xenobiotica 12: 323–328

    PubMed  CAS  Google Scholar 

  • Jenkins T, Lehmann H, Nurse GP (1974) Public health and genetic constitution of the Sab (“Bushmen”): carbohydrate metabolism and acetylator status of the Kung of Tsumkwe in the North-Western Kalahari. Br Med J 2: 23–26

    PubMed  CAS  Google Scholar 

  • Karim AKMB, Elfellah MS, Evans DAP (1981) Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution. J Med Genet 18: 325–330

    PubMed  CAS  Google Scholar 

  • Lee EJD, Lim JME, Feng P-H (1985) Acetylator phenotype in Chinese patients with spontaneous systemic lupus erythematosus. Syngapore Med J 26: 295–299

    CAS  Google Scholar 

  • Lilyin ET, Korunskaya MP, Meksin VA, Taelicheva LV, Shapiro EF (1983) The distribution of acetylator phenotypes in Moscow population. Genetika 19: 1378–1380

    Google Scholar 

  • Lilyin ET, Korunskaya MP, Meksin VA, Drozdov ES, Nasarov VV, Monastyrskaya AR (1984) The distribution of acetylator phenotypes in normal individuals and the patients suffering from alcoholism among Moscow urban population. Genetika 20: 1557–1559

    Google Scholar 

  • Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT (1979) Nacetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71–79

    PubMed  CAS  Google Scholar 

  • Nhachi CFB (1988) Polymorphic acetylation of sulphamethazine in a Zimbabwe population. J Med Genet 25: 29–31

    PubMed  CAS  Google Scholar 

  • Odeigah PGC, Okunowo MA (1989) High frequency of the rapid isoniazid acetylator phenotype in Lagos ( Nigeria ). Hum Hered 39: 26–31

    PubMed  CAS  Google Scholar 

  • Paik YK, Cho YH, Kim IK, Benkmann HG, Goedde HW (1988) Pharmacogenetic studies in South Korea: serum cholinesterase and N-acetyltransferase polymorphisms. Korean J Genet 10: 272–278

    Google Scholar 

  • Parthasarathy R, Raghupati Sarma G, Janardhanam B, Ramachandran P, Santha T, Sivasubramaian S, Somasundaram PR, Tripathy SP (1986) Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 67: 99–108

    PubMed  CAS  Google Scholar 

  • Paulsen O, Nilsson LG (1985) Distribution of acetylator phenotype in relation to age and sex in Swedish patients. Eur J Clin Pharmacol 28: 311–315

    PubMed  CAS  Google Scholar 

  • Penketh RJA, Gibreig SFA, Nurse GT, Hopkinson DA (1983) Acetylator phenotypes in Papua New Guinea. J Med Genet 20: 39–40

    Google Scholar 

  • Peters JH, Gordon GT, Karat ABA (1975) Polymorphic acetylation of the antibacterials, sulfamethazine and dapsone, in South Indian subjects. Am J Trop Med Hyg 24: 641–648

    PubMed  CAS  Google Scholar 

  • Sardas S, Karakaya AE, Cok I (1986a) Determination of the acetylator phenotype in a Turkish population. Clin Genet 29: 185–186

    PubMed  CAS  Google Scholar 

  • Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W (1991) Caffeine as a metabolic probe: validation of its use for acetylator phenotyping ( Various ethnic groups ). Clin Pharmacol Ther 49: 648–657

    PubMed  CAS  Google Scholar 

  • Viznerova A, Slavikova Z, Ellard GA (1973) The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine. Tubercle 54: 67–76

    PubMed  CAS  Google Scholar 

II. Phenotypes of Hydroxylation

  • Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533–537

    PubMed  CAS  Google Scholar 

  • Arias TD, Jorge LF, Inaba T (1986) No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama. Br J Clin Pharmacol 21: 547–548

    PubMed  CAS  Google Scholar 

  • Arias TD, Jorge LF, Lee D, Barrantes R, Inaba T (1988a) The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers. Clin Pharmacol Ther 43: 456–465

    PubMed  CAS  Google Scholar 

  • Arias TD, Inaba T, Cooke RG, Jorge LF (1988b) A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymi Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway. Clin Pharmacol Ther 44: 343–352

    PubMed  CAS  Google Scholar 

  • Arvela P, Kirjarinta M, Kirjarinta M, Karki N, Pelkonen O (1988) Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol 26: 601–603

    PubMed  CAS  Google Scholar 

  • Benitez J, Llerena A, Cobaleda (1988) Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 44: 74–77

    PubMed  CAS  Google Scholar 

  • Bressolette L, Berthou F, Riche C, Mottier D, Floch HH (1990) Polymorphisme génétique d’acetylation et d’hydroxylation dans la population bretonne. Therapie 45: 99–103

    Google Scholar 

  • Brøsen K (1986) Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol 22: 415–419

    PubMed  Google Scholar 

  • Brøsen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh) 57: 357–360

    Google Scholar 

  • Clasen K, Madsen L, Brøsen K, Albøge K, Misfeldt S, Gram LF (1991) Sparteine and mephenytoin oxidation: genetic polymorphisms in East and West Greenland. Clin Pharmacol Ther 49: 624–631

    PubMed  CAS  Google Scholar 

  • Dayer P, Balant LP, Courvoisier F, Küpfer A, Kubli A, Gorgia A, Fabre J (1982) The genetic control of bufuralol metabolism in man ( Switzerland ). Eur J Drug Metab Pharmacokinet 7: 73–77

    PubMed  CAS  Google Scholar 

  • Dayer P, Balant L, Küpfer A, Courvoisier F, Fabre J (1983) Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents (bufuralol in Switzerland). Eur J Clin Pharmacol 24: 797–799

    PubMed  CAS  Google Scholar 

  • Dick B, Küpfer A, Molnàr J, Braunschweig S, Preisig R (1982) Hydroxylierungsdefekt für Medikamente ( Typus Debrisoquin) in einer Stichprobe der Schweizerischen Bevölkerung. Schweiz Med Wochenschr 112: 1061–1067

    PubMed  CAS  Google Scholar 

  • Drøhse A, Bathum L, Brøsen K, Gram LF (1989) Mephenytoin and sparteine oxidation: genetic polymorphism in Denmark. Br J Clin Pharmacol 27: 620–625

    PubMed  Google Scholar 

  • Eichelbaum M, Woolhouse NM (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol 28: 79–83

    PubMed  CAS  Google Scholar 

  • Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidative in a white British population. Br J Med Genet 17: 102–105

    CAS  Google Scholar 

  • Horai Y, Ishizaki T, Ishikawa K (1988) Metoprolol oxidation in a Japanese population: evidence for only one poor metabolizer among 262 subjects. Br J Clin Pharmacol 26: 807–808

    PubMed  CAS  Google Scholar 

  • Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, Lia CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46: 198–207

    PubMed  CAS  Google Scholar 

  • Inaba T, Jurima M, Nakano M, Kalow W (1984) Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther 36: 670–676

    PubMed  CAS  Google Scholar 

  • Inaba T, Jorge LF, Arias TD (1988) Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br J Clin Pharmacol 25: 75–79

    PubMed  CAS  Google Scholar 

  • Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ (1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 23: 482–485

    PubMed  CAS  Google Scholar 

  • Islam SI, Idle JR, Smith RL (1980) The polymorphic 4-hydroxylation of debrisoquin in a Saudi Arab population. Xenobiotica 10: 819–825

    PubMed  CAS  Google Scholar 

  • Iyun AO, Lennard MS, Tucker GT, Woods HF (1986) Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40: 387–394

    PubMed  CAS  Google Scholar 

  • Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35: 167–171

    PubMed  CAS  Google Scholar 

  • Jurima M, Inaba T, Kadar D, Kalow W (1985) Genetic polymorphism of mephenytoin p(41)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 19: 483–487

    PubMed  CAS  Google Scholar 

  • Kallio J, Lindberg R, Huuponen R, lisalo E (1988) Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br J Clin Pharmacol 26: 791–795

    PubMed  CAS  Google Scholar 

  • Kalow W, Otton SV, Kadar D, Endrenyi L, Inaba T (1980) Ethnic differences in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol 58: 1142–1144

    PubMed  CAS  Google Scholar 

  • Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man ( Switzerland ). Eur J Clin Pharmacol 26: 753–759

    PubMed  Google Scholar 

  • Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G, Pessayre D (1987) Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 24: 676–679

    PubMed  CAS  Google Scholar 

  • Leclercq V, Desager JP, van Nieuwenhuyze Y, Harvengt C (1987) Prevalence of drug hydroxylator phenotype in Belgium. Eur J Clin Pharmacol 33: 439–440

    PubMed  CAS  Google Scholar 

  • Lennard MS, Tucker GT, Woods HF, Silas JH, Iyun AO (1989) Stereoselective metabolism of metoprolol in Caucasians and Nigerians—relationship to debrisoquin oxidation phenotype. Br J Clin Pharmacol 27: 613–616

    PubMed  CAS  Google Scholar 

  • Lou YC, Ying L, Bertilsson L, Sjöqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2: 852–853

    PubMed  CAS  Google Scholar 

  • Mahgoub A, Idle JR, Smith RL (1979) A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 9: 51–56

    PubMed  CAS  Google Scholar 

  • Mbanefo C, Bababunmi EA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 10: 811–818

    PubMed  CAS  Google Scholar 

  • Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408

    PubMed  CAS  Google Scholar 

  • Peart GF, Boutagy J, Shenfield GM (1986) Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol 21: 465–471

    PubMed  CAS  Google Scholar 

  • Relling MV, Cherries J, Schell MJ, Petros WP, Meyer WH, Evans WE (1991) Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 50: 308–313

    PubMed  CAS  Google Scholar 

  • Schellens JHM, Danhof M, Breimer DD (1986) The poor metabolizer incidence of sparteine, mephenytoin and nifedipine in a Dutch population. Acta Pharmacol Toxicol (Copenh) Suppl 5: 252

    Google Scholar 

  • Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431–435

    PubMed  CAS  Google Scholar 

  • Sommers DK, Moncrieff J, Avenant J (1989) Metoprolol a-hydroxylation polymorphism in the San Bushmen of Southern Africa. Hum Toxicol 8: 39–43

    PubMed  CAS  Google Scholar 

  • Sommers DK, Moncrieff J, Avenant J (1989) Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 8: 365–368

    PubMed  CAS  Google Scholar 

  • Szórády I, Sánta A (1987) Drug hydroxylator phenotype in Hungary. Eur J Clin Pharmacol 32: 325

    PubMed  Google Scholar 

  • Veronese ME, McLean S (1991) Debrisoquine oxidation polymorphism in a Tasmanian population. Eur J Clin Pharmacol 40: 529–532

    PubMed  CAS  Google Scholar 

  • Vinks A, Inaba T, Otton SV, Kalow W (1982) Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 31: 23–29

    PubMed  CAS  Google Scholar 

  • Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36: 773–780

    PubMed  CAS  Google Scholar 

  • Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL (1979) Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 26: 584–591

    PubMed  CAS  Google Scholar 

  • Woolhouse NM, Eichelbaum, Oates NS, Idle JR, Smith RL (1985) Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 37: 512–521

    PubMed  CAS  Google Scholar 

  • Yue QY, Bertilsson L, Dahl-Puustinen ML, Sawe J, Sjoqvist F, Johansson I, Ingelman-Sundberg M (1989) Dissociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 2: 870

    PubMed  CAS  Google Scholar 

III. Pharmacokinetics

  • Branch RA, Salih SY, Homeida M (1978) Racial differences in drug metabolizing ability: a study with antipyrine in the Sudan. Clin Pharmacol Ther 24: 283–286

    PubMed  CAS  Google Scholar 

  • Buchanan N, Bill P, Moodley G, Eyberg C (1977) The metabolism of phenobarbitone in black patients. S Afr Med J 52: 394–395

    PubMed  CAS  Google Scholar 

  • Desai NK, Sheth UK, Mucklow JC, Fraser HS, Bulpitt CJ, Jones SW, Dollery CT (1980) Antipyrine clearance in Indian villagers. Br J Clin Pharmacol 9: 387–394

    PubMed  CAS  Google Scholar 

  • Chan E, Ti TY, Lee HS (1990) Population pharmacokinetics of phenytoin in Singapore Chinese. Eur J Clin Pharmacol 39: 177–181

    PubMed  CAS  Google Scholar 

  • De Sommers K, Van Staden DA, Moncrieff J, Schoenman HS (1985) Paracetamol metabolism in African villagers. Hum Toxicol 4: 385–389

    PubMed  CAS  Google Scholar 

  • De Sommers K, Moncrieff J, Avenant JC (1987) Paracetamol conjugation: an interethnic and dietary study. Hum Toxicol 6: 407–409

    PubMed  CAS  Google Scholar 

  • Ghoneim MM, Korttila K, Chiang CK, Jacobs L, Schoenwald RD, Mewaldt SP, Kabaya KO (1981) Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 29: 749–756

    PubMed  CAS  Google Scholar 

  • Kalow W, Tang BK, Kadar D, Endrenyi L, Chan FY (1979) A method for studying drug metabolism in populations: racial differences in amobarbital metabolism. Clin Pharmacol Ther 26: 766–776

    PubMed  CAS  Google Scholar 

  • Kromann N, Christiansen J, Flachs H, Dam M, Hvidberg EF (1981) Differences in single dose phenytoin kinetics between Greenland Eskimos and Danes. Ther Drug Monit 3: 239–245

    PubMed  CAS  Google Scholar 

  • Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ (1987) Differences in diazepam pharmacokinetics in Chinese and white Caucasians—relation to body lipid stores. Eur J Clin Pharmacol 32: 211–215

    PubMed  CAS  Google Scholar 

  • Pi EH, Tran-Johnson TK, Walker NR, Cooper TB, Suckow RF, Gray GE (1989) Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol Bull 25: 483–487

    PubMed  CAS  Google Scholar 

  • Rudorfer MV, Lane EA, Chang WH, Zhang M, Potter WZ (1984) Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 17: 433–440

    PubMed  CAS  Google Scholar 

  • Spector R, Choudhury AK, Chiang CK, Goldberg MJ, Ghoneim MM (1980) Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther 28: 229–234

    PubMed  CAS  Google Scholar 

  • Zhou HH, Wood AJJ (1990) Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)-and (+)-propranolol. Clin Pharmacol Ther 47: 719–723

    PubMed  CAS  Google Scholar 

  • Zhou HH, Adedoyin A, Wilkinson GR (1990) Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 48: 10–17

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. L. P. Balant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. G. Welling
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmacokinetics/Drug Metabolism Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, 2800 Plymouth Road, 48105-1047, Ann Arbor, MI, USA

    Peter G. Welling Ph.D., D.Sc. (Vice President) (Vice President)

  2. Clinical Research Unit, Department of Psychiatry, 47, Rue du XXXI Décembre, CH-1207, Geneva, Switzerland

    Luc P. Balant Ph.D. (Reader) (Reader)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Balant, L.P., Welling, P.G. (1994). Interethnic Differences in Drug Disposition and Response: Relevance for Drug Development, Licensing, and Registration. In: Welling, P.G., Balant, L.P. (eds) Pharmacokinetics of Drugs. Handbook of Experimental Pharmacology, vol 110. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78680-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78680-8_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78682-2

  • Online ISBN: 978-3-642-78680-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation